What is the NOPAIN Act?

Federal law mandating separate Medicare reimbursement for qualifying non-opioid pain management therapies used during outpatient surgeries (ASC and HOPD settings).

Effective January 1, 2025 – December 31, 2027.

Why It Matters to Providers Now

New Reimbursement Opportunities
Non-opioid devices like The Morph Device will now be paid separately — creating a new revenue stream outside of bundled surgical payments.

Regulatory and Risk Mitigation
Meeting federal initiatives to reduce opioid exposure positions your practice ahead of coming compliance standards.

Patient Demand and Market Differentiation
Patients increasingly seek safer, opioid-free recovery options — offering alternatives like The Morph Device helps you attract, retain, and better serve your patients.

Improved Outcomes, Fewer Complications
Non-opioid pain management supports faster recovery, lower readmission risk, and higher satisfaction rates.

Enhanced Clinical and Economic Performance
Deliver better care while strengthening financial outcomes for your practice or center.

The NOPAIN Act Changes the Game for Providers

Separate Reimbursement: Providers are now financially rewarded for using FDA-cleared, non-opioid alternatives like The Morph Device.

Revenue Growth Opportunity: Adds new billable services without additional surgical complexity.

Regulatory Alignment: Proactively meets new federal standards for opioid-sparing care.

Patient Demand: Addresses rising patient expectations for safer, faster recovery options.